Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Ryanair at 5-month low 🚩Jet fuel price surge pressures aerospace industry
Wall Street tries to stop the sell-off as oil surges 🚩Alibaba drops 7% amid earnings miss
Stock of the Week: Micron Technology at the Golden Moment of the Memory Cycle
US Open: War Jitters and Hot Inflation Freeze Wall Street Sentiment